Targets › BUTYRATE
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Jun 2029.
Open in Phaseline: the race on BUTYRATE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Nebraska | SunButyrate-TG Short-chain fatty acid (SCFA) supplement; promotes gut health and microbiome function | BUTYRATE | Phase 1 | Congenital Heart Disease (CHD) | Jun 2029 |
Congenital Heart Disease (CHD) (1)
small molecule (1)
University of Nebraska (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.